Bristol Recharges Kai Heart Attack Candidate
Executive Summary
Just because a marriage ends with a breakup doesn't mean a happy union with someone else isn't in the stars - especially when it comes to partnerships between big pharma and biotech
You may also be interested in...
Amgen Planned Acquisition Of KAI Would Bring In Replacement For Sensipar
Amgen will get KAI’s late-stage-ready asset for a small upfront price and gives itself a logical line extension to its chronic kidney disease drug Sensipar.
“Bio-buck” Deals A Good Risk-Sharing Strategy, Pharma Execs Say At BIO
Bio-buck deals, those back-end-loaded, early-stage collaborations that grab headlines because of the big dollars promised, are a win-win risk share, big pharma execs say
“Bio-buck” Deals A Good Risk-Sharing Strategy, Pharma Execs Say At BIO
Bio-buck deals, those back-end-loaded, early-stage collaborations that grab headlines because of the big dollars promised, are a win-win risk share, big pharma execs say